Pulvinar Stimulation in Epilepsy: a Pilot Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-15

Study Completion Date

2026-10-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Deep brain stimulation (DBS) is one of the neuromodulation techniques that can be indicated in patients suffering from refractory epilepsies, especially when an open resection has failed or is not indicated, and vagal nerve stimulation (VNS) demonstrated no efficacy. Benefits such as reduction of seizure frequency have been shown for thalamic stimulation of the anterior thalamic nucleus (ANT), however it has limited efficacy and non-optimal neurocognitive outcome, making the search for other targets crucial in this context. We propose a novel target for DBS stimulation in drug-resistant epilepsy namely the medial pulvinar thalamic nucleus (PuM).

This target has been chosen based on previous retrospective studies demonstrating that PuM is involved during focal seizures and in loss of consciousness and seizure termination. PuM stimulation also showed potential encouraging results based on the feasibility and safetu studies recently published.

The main objective is to obtain a significant percentage of seizure reduction after 12 months of PuM stimulation compared to baseline period. Quality of life and the relationship with psychiatric and cognitive comorbidities will also be assessed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Electrical Brain Stimulation to Reduce Epileptic Seizures

NCT00344877

Temporal Lobe Epilepsy

COMPLETED

Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Intractable Epilepsy

NCT04771065

Refractory Epilepsy

UNKNOWN

A Deep Brain Stimulation System in Epilepsy: Tracking Neural Excitability

NCT03465163

Epilepsy Nodular Heterotopia

COMPLETED NA

Optimization of the Parameters of Vagal Nerve Stimulation

NCT04693221

Epilepsy

ACTIVE_NOT_RECRUITING NA

Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy

NCT02076698

Partial Epilepsy Surgery

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Epilepsy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pulvinar stimulation

Medial pulvinar deep brain stimulation

Group Type EXPERIMENTAL

Pulvinar deep brain stimulation

Intervention Type DEVICE

Stimulation of the medial pulvinar

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pulvinar deep brain stimulation

Stimulation of the medial pulvinar

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age: between 18 and 60 years old
* Focal or multifocal drug-resistant epilepsy not operable or failure of epilepsy surgery
* Vagal nerve stimulation failure (after at least 1 year of treatment or stopped early for worsening seizures)
* Either patients with epilepsy whose characteristics suggest that it may respond better to stimulation of the pulvinar than the anterior thalamic nucleus stimulation (i.e. posterior quadrant epilepsy, motor/premotor epilepsy, operculo-insular epilepsy, temporal plus epilepsy, lateral temporal epilepsy) or/and patients with previous anterior thalamic nucleus stimulation failure (after 2 years of treatment or stopped early for worsening seizures)
* Number of seizures \> 4 / month during the baseline (3 months) and before the V0 for at least 3 months
* Total IQ \> 55
* Give written consent to the study after receiving clear information
* Be a beneficiary or affiliated to a health insurance plan
* For women of childbearing potential, a pregnancy test must be negative before inclusion.

Exclusion Criteria

* Difficulty to read or understand the French language, or inability to understand the information regarding the study.
* Generalized epilepsy
* Presenting contraindication to MRI, a serious intercurrent pathology, a progressive brain tumor.
* Pregnancy or breastfeeding
* Present a history of attempted suicide in the 6 months prior to inclusion or a score ≥ 2 in item 10 of the Montgomery and Asberg Depression Scale (MADRS).
* Present a surgical or anaesthetic contraindication.
* Require long-term anticoagulant or platelet aggregation therapy.
* Hereditary bleeding disorders of coagulation
* Non obliterated AVM
* History of Herpes virus brain infection
* Total IQ below 55.
* Patients with less than 4 seizures a month
* To be hospitalized under duress (HO / HDT)
* Major under guardianship or curatorship
* Person deprived of liberty by judicial decision
* Patient currently participating in another clinical trial or having participated in a clinical trial in the month prior to inclusion

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No